Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin 6‑month subcutaneous formulation in previously castrated advanced/metastatic prostate cancer
2021-005719-29Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Primary endpoint: Maintenance of castrate testosterone levels over treatment period. Started Apr 2022; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-005719-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005719-29.